Xiwang Pharmaceutical Co., Ltd. China

At the recently concluded CPHI 2026 Global Pharmaceutical Ingredients Exhibition (Frankfurt), Xiwang Pharmaceutical Co., Ltd. China, representing the Chinese pharmaceutical raw material industry, made a brilliant appearance. With its high-quality glucose raw materials and strong technological capabilities, it attracted attention from customers in over 100 countries and regions worldwide, securing over US$50 million in intended orders on-site, setting a new record.

CPHI, one of the world's most influential pharmaceutical industry exhibitions, is an important platform for companies to showcase their strength and expand into international markets. Xiwang Pharmaceutical Co., Ltd. China's participation in this exhibition focused on showcasing its core product—high-purity glucose raw materials—as well as its latest glucose derivatives, including sodium gluconate and maltodextrin. These products, with their superior quality, stable performance, and competitive pricing, won high recognition from international customers.

The head of Xiwang Pharmaceutical's International Business Department stated, "As China's largest pharmaceutical glucose production base, Xiwang Pharmaceutical Co., Ltd. China is committed to providing high-quality products and services to global customers. In recent years, the company has actively responded to the national 'Belt and Road' initiative, accelerating its international expansion. Its products have been exported to more than 50 countries and regions worldwide, establishing a positive image for 'Made in China' in the international market. This exhibition not only showcases the company's product advantages but also provides an opportunity to build closer cooperative relationships with international customers." During the exhibition, Xiwang Pharmaceutical Co., Ltd. China also reached strategic cooperation agreements with several internationally renowned pharmaceutical companies, including a long-term supply agreement with a large German pharmaceutical group to provide high-quality glucose raw materials for antibiotic production; and a collaboration with a French biopharmaceutical company to develop novel pharmaceutical excipients. These collaborations will further enhance Xiwang Pharmaceutical's influence in the international market and propel China's pharmaceutical raw material industry to the center stage globally.

CONTACT INFORMATION

Website:https://www.xiwang-pharmaceutical.com/

Phone:+8615371019725

Email:sales7@boxa-chem.com